- Home
- HQ vs LTGO Comparison
HQ vs LTGO Comparison
Compare HQ & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HQ | LTGO |
|---|---|---|
| Founded | 2018 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2025 | 2026 |
Fundamental Metrics
Financial Performance| Metric | HQ | LTGO |
|---|---|---|
| Price | $15.37 | $24.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 255.5K | ★ 318.2K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.29 | $17.22 |
| 52 Week High | $45.00 | $25.93 |
Technical Indicators
Market Signals| Indicator | HQ | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 87.86 |
| Support Level | $9.79 | $18.46 |
| Resistance Level | $21.00 | N/A |
| Average True Range (ATR) | 1.95 | 1.46 |
| MACD | 0.25 | 0.58 |
| Stochastic Oscillator | 50.00 | 92.76 |
Price Performance
Historical ComparisonAbout HQ Horizon Quantum Holdings Ltd. Class A Ordinary Shares
Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.